Andexanet alfa (PRT064445, PRT4445) is a drug under investigation as a potential antidote for factor Xa inhibitors, a group of anticoagulant (anti-blood clotting) drugs that includes rivaroxaban, apixaban and edoxaban. It is being developed by Portola Pharmaceuticals.
Video Andexanet alfa
Mechanism of action
Andexanet alfa is a biologic agent, a modified recombinant derivative of factor Xa (fXa). It acts as a decoy receptor -- it has a higher affinity to the fXa inhibitor than natural fXa, and consequently the inhibitor binds to the drug rather than to fXa itself. The drug does not seem to be effective against the factor IIa inhibitor dabigatran.
Maps Andexanet alfa
Studies
In rats, andexanet alfa corrected increases in blood loss resulting from anticoagulation by enoxaparin and fondaparinux. A small, phase I safety and tolerability study in humans has been completed and a phase II trial is under way as of January 2014. Interim results from this study showed that it reversed the action of rivaroxaban within two minutes.
In 2015, the first randomized control trial showed that andexanet alfa reversed the effects of factor Xa inhibitor drugs apixaban and rivaroxaban safely and effectively.
See also
Other anticoagulant antidotes
- Ciraparantag
- Idarucizumab
- Vitamin K
References
Source of article : Wikipedia
0 Comments